New Research Coverage Highlights Altair Engineering, Genomic Health, Seres Therapeutics, REV Group, MACOM Technology Solutions, and New Mountain Finance — Consolidated Revenues, Company Growth, and Ex

New Research Coverage Highlights Altair Engineering, Genomic Health, Seres Therapeutics, REV Group, MACOM Technology Solutions, and New Mountain Finance — Consolidated Revenues, Company Growth, and Expectations for 2018

NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Altair Engineering Inc. (NASDAQ:ALTR), Genomic Health, Inc. (NASDAQ:GHDX), Seres Therapeutics, Inc. (NASDAQ:MCRB), REV Group, Inc. (NYSE:REVG), MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI), and New Mountain Finance Corporation (NYSE:NMFC), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

ALTR DOWNLOAD: http://Fundamental-Markets.com/register/?so=ALTR
GHDX DOWNLOAD: http://Fundamental-Markets.com/register/?so=GHDX
MCRB DOWNLOAD: http://Fundamental-Markets.com/register/?so=MCRB
REVG DOWNLOAD: http://Fundamental-Markets.com/register/?so=REVG
MTSI DOWNLOAD: http://Fundamental-Markets.com/register/?so=MTSI
NMFC DOWNLOAD: http://Fundamental-Markets.com/register/?so=NMFC

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Altair Engineering Inc. (NASDAQ:ALTR), Genomic Health, Inc. (NASDAQ:GHDX), Seres Therapeutics, Inc. (NASDAQ:MCRB), REV Group, Inc. (NYSE:REVG), MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI), and New Mountain Finance Corporation (NYSE:NMFC) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed October 16th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

ALTAIR ENGINEERING INC. (ALTR) REPORT OVERVIEW

Altair Engineering's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Altair Engineering reported revenue of $95.57MM vs $81.65MM (up 17.05%) and analysts estimated basic earnings per share $0.02 vs -$0.14. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Altair Engineering reported revenue of $333.33MM vs $313.24MM (up 6.41%) and analysts estimated basic earnings per share -$1.89 vs $0.21. Analysts expect earnings to be released on November 29th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.57. The estimated EPS forecast for the next fiscal year is $0.55 and is expected to report on March 20th, 2019.

To read the full Altair Engineering Inc. (ALTR) report, download it here: http://Fundamental-Markets.com/register/?so=ALTR

-----------------------------------------

GENOMIC HEALTH, INC. (GHDX) REPORT OVERVIEW

Genomic Health's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Genomic Health reported revenue of $95.62MM vs $85.49MM (up 11.85%) and analysts estimated basic earnings per share $0.23 vs -$0.08. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Genomic Health reported revenue of $340.75MM vs $327.87MM (up 3.93%) and analysts estimated basic earnings per share -$0.11 vs -$0.42. Analysts expect earnings to be released on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was $0.03. The estimated EPS forecast for the next fiscal year is $0.76 and is expected to report on March 14th, 2019.

To read the full Genomic Health, Inc. (GHDX) report, download it here: http://Fundamental-Markets.com/register/?so=GHDX

-----------------------------------------

SERES THERAPEUTICS, INC. (MCRB) REPORT OVERVIEW

Seres Therapeutics' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Seres Therapeutics reported revenue of $4.61MM vs $3.01MM (up 53.02%) and analysts estimated basic earnings per share -$0.68 vs -$0.69. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Seres Therapeutics reported revenue of $32.10MM vs $21.77MM (up 47.48%) and analysts estimated basic earnings per share -$2.21 vs -$2.30. Analysts expect earnings to be released on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was -$0.17. The estimated EPS forecast for the next fiscal year is -$2.75 and is expected to report on March 14th, 2019.

To read the full Seres Therapeutics, Inc. (MCRB) report, download it here: http://Fundamental-Markets.com/register/?so=MCRB

-----------------------------------------

REV GROUP, INC. (REVG) REPORT OVERVIEW

REV Group's Recent Financial Performance

For the three months ended July 31st, 2018 vs July 31st, 2017, REV Group reported revenue of $597.70MM vs $595.60MM (up 0.35%) and basic earnings per share $0.29 vs $0.24 (up 20.83%). For the twelve months ended October 31st, 2017 vs October 31st, 2016, REV Group reported revenue of $2,267.78MM vs $1,926.00MM (up 17.75%) and analysts estimated basic earnings per share $0.52 vs $0.59 (down 11.86%). Analysts expect earnings to be released on December 18th, 2018. The report will be for the fiscal period ending October 31st, 2018. The reported EPS for the same quarter last year was $0.44. The estimated EPS forecast for the next fiscal year is $1.50 and is expected to report on December 18th, 2018.

To read the full REV Group, Inc. (REVG) report, download it here: http://Fundamental-Markets.com/register/?so=REVG

-----------------------------------------

MACOM TECHNOLOGY SOLUTIONS HOLDINGS, INC. (MTSI) REPORT OVERVIEW

MACOM Technology Solutions' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, MACOM Technology Solutions reported revenue of $137.87MM vs $194.56MM (down 29.13%) and analysts estimated basic earnings per share -$1.32 vs -$0.43. For the twelve months ended September 30th, 2017 vs September 30th, 2016, MACOM Technology Solutions reported revenue of $698.77MM vs $544.34MM (up 28.37%) and analysts estimated basic earnings per share -$2.79 vs $0.03. Analysts expect earnings to be released on November 13th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.35. The estimated EPS forecast for the next fiscal year is $0.47 and is expected to report on November 13th, 2018.

To read the full MACOM Technology Solutions Holdings, Inc. (MTSI) report, download it here: http://Fundamental-Markets.com/register/?so=MTSI

-----------------------------------------

NEW MOUNTAIN FINANCE CORPORATION (NMFC) REPORT OVERVIEW

New Mountain Finance's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, New Mountain Finance reported interest income of $54.60MM vs $50.02MM (up 9.15%) and analysts estimated basic earnings per share $0.30 vs $0.36 (down 16.67%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, New Mountain Finance reported interest income of $197.81MM vs $168.08MM (up 17.68%) and analysts estimated basic earnings per share $1.47 vs $1.72 (down 14.53%). Analysts expect earnings to be released on November 7th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.33. The estimated EPS forecast for the next fiscal year is $1.39 and is expected to report on February 27th, 2019.

To read the full New Mountain Finance Corporation (NMFC) report, download it here: http://Fundamental-Markets.com/register/?so=NMFC

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.